688202 Stock Overview
A drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Shanghai Medicilon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥29.69 |
| 52 Week High | CN¥98.89 |
| 52 Week Low | CN¥28.80 |
| Beta | 0.71 |
| 1 Month Change | -16.22% |
| 3 Month Change | -34.20% |
| 1 Year Change | -68.20% |
| 3 Year Change | -89.28% |
| 5 Year Change | n/a |
| Change since IPO | -18.04% |
Recent News & Updates
Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?
Jun 07
Market Cool On Shanghai Medicilon Inc.'s (SHSE:688202) Revenues Pushing Shares 27% Lower
Apr 25Shareholder Returns
| 688202 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -0.3% | 1.9% | 0.06% |
| 1Y | -68.2% | -37.7% | -16.1% |
Return vs Industry: 688202 underperformed the CN Life Sciences industry which returned -37.7% over the past year.
Return vs Market: 688202 underperformed the CN Market which returned -16.1% over the past year.
Price Volatility
| 688202 volatility | |
|---|---|
| 688202 Average Weekly Movement | 8.4% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688202's share price has been volatile over the past 3 months.
Volatility Over Time: 688202's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 2,600 | Chunlin Chen | www.medicilon.com.cn |
Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems.
Shanghai Medicilon Inc. Fundamentals Summary
| 688202 fundamental statistics | |
|---|---|
| Market cap | CN¥4.00b |
| Earnings (TTM) | -CN¥172.33m |
| Revenue (TTM) | CN¥1.17b |
3.4x
P/S Ratio-23.2x
P/E RatioIs 688202 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688202 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.17b |
| Cost of Revenue | CN¥1.04b |
| Gross Profit | CN¥130.84m |
| Other Expenses | CN¥303.17m |
| Earnings | -CN¥172.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 11.15% |
| Net Profit Margin | -14.68% |
| Debt/Equity Ratio | 12.6% |
How did 688202 perform over the long term?
See historical performance and comparison